Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

GTx's Toremifene 80 Mg Increased Bone Mineral Density In Multiple Clinically Relevant Subpopulations Of Prostate Cancer Patients
GTx, Inc. (Nasdaq: GTXI) announced the presentation of data demonstrating that toremifene 80 mg treatment compared to placebo increased bone mineral density (BMD) in multiple clinically relevant subpopulations of men with prostate cancer on androgen deprivation therapy (ADT). The data, an analysis of results of the recent Phase III clinical trial evaluating toremifene 80 mg for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer, were presented yesterday at the 2009 Annual Meeting of the American Society of Clinical Oncology.
generic viagra online
Death Penalty And Mental Illness: Families Of Victims Speak Out At National Convention; "Double Tragedies" Report Released
For the first time, families of murder victims have joined with families of persons with mental illness who have been executed to speak out against the death penalty.
News of the day
Study Shows How Stroke Affects Hand Function; Provides Roadmap For Rehab
A person whose hand function has been affected by a stroke can release an object more quickly when the affected arm is supported on a platform, but the support does not make it easier to grip the object, according to a new study. The study also found that active muscle-stretching exercises improved how quickly the stroke survivor could grip an object, but made release of the object more difficult. These findings show how a stroke affects hand function, and provide a roadmap for rehabilitation.
Medical Devices

New York Times Examines Debate Surrounding Use Of Experimental Treatments In Terminally Ill Patients

Some patient advocates are lobbying to legalize "compassionate use" of experimental drugs for people with terminal illnesses who have exhausted other treatments, prompting a debate about how and when to provide such patients with treatments that could prolong their lives, the New York Times reports. Most insurers do not cover unproven treatments, and physicians have concerns that using experimental treatment could give patients false hope and cause unnecessary pain. Drugmakers are concerned that if there are unfavorable outcomes from providing patients with an unproven treatment, it could hurt the drug"s chances of receiving FDA approval. At the same time, FDA does not want to grant drugs and their makers the opportunity to skip clinical trials. Currently, patients must individually apply to receive treatments through compassionate use (Harmon, New York Times, 5/17). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009